Cardiac Safety Services are an essential aspect of drug
development and clinical research. These services focus on monitoring the
potential cardiac effects of a drug on patients during clinical trials, as well
as evaluating the safety of drugs that are already on the market. Cardiac
safety assessments help to identify potential cardiovascular risks associated
with a drug, and provide critical information for regulatory approval.
Cardiac safety services typically include a range of tests,
including electrocardiograms (ECGs), echocardiography, and cardiac imaging.
These tests help to monitor changes in heart rate, rhythm, and function, as
well as assess any potential cardiovascular risks associated with a drug.
Cardiac safety assessments are an essential component of the
drug development process, and are required by regulatory agencies such as the
FDA and EMA. Failure to adequately assess cardiac safety can result in delays
in drug approval, or even the withdrawal of a drug from the market.
At a basic level, cardiac safety services involve the
identification and monitoring of potential cardiovascular risks associated with
a drug. This can include monitoring for changes in heart rate, rhythm, and
function, as well as evaluating the effects of a drug on blood pressure,
vascular function, and other key indicators of cardiovascular health.
In addition to monitoring the cardiovascular effects of a
drug, cardiac safety services may also involve the development and
implementation of risk management strategies. These strategies may include the
use of specific patient populations or dosage regimens, as well as the
development of monitoring plans to detect any potential cardiac adverse events.
Cardiac Safety Services Market Dynamics
Drivers in Cardiac
Safety Services Market
The cardiac safety services market is influenced by several
factors, including drivers and opportunities. One of the key drivers of the
market is the increasing R&D expenditure in the pharmaceutical and
biopharmaceutical industry. Pharmaceutical companies invest heavily in R&D
to deliver high-quality and innovative products to the market. This has
resulted in the growth of preclinical and clinical services, including cardiac
safety evaluation, to ensure the safety and efficacy of the therapeutic drug before
launching in the market.
Collaborative R&D efforts and heavy R&D investments
by top pharmaceutical companies have contributed to the growth of the market.
For example, ERT has launched a Phase I QT Center of excellence to provide
cardiac safety assessment in Phase I studies. The company also offers an
integrated ECG analysis platform, EPQT, to provide sponsors with actionable and
reliable information about the cardiac safety profiles of their compounds at
the earliest stage of the drug development process.
Opportunities in
Cardiac Safety Services Market
Another driver of the market is the growth in the
biosimilars and biologics markets. With more than half of the drug candidates
in the discovery stage being biologics, pharmaceutical and biopharmaceutical
companies are heavily investing in R&D to develop these molecules.
Biosimilars are cost-effective compared to small molecules, and specialized
testing services are required for their safety assessment. This presents
opportunities for safety assessment providers to expand their portfolios and
capabilities.
Clinical trials are vital for discovering and developing new
drugs for disease treatment. They are the most effective way to ensure the
safety and efficacy of therapeutic drugs before they are launched in the market
and consumed by humans. Thus, cardiac safety evaluation is an essential part of
the drug development process, and the growth in the number of drug launches
would help the industry flourish during the forecast period. For instance, ERT
has announced a new alert service called Rapid ECG, which expedites analysis of
screening and other ECGs to optimize patient enrollment and ensure patient
safety in large, complex global clinical trials.
Restraints in Cardiac
Safety Services Market
The costly nature of cardiac safety services poses a
significant challenge to the development of new drugs, contributing to the
decline in the number of drugs approved in the US and posing a threat to public
health. Conducting evaluations of off-target drug effects can be time-consuming
and expensive, often resulting in the termination of many new drug candidates.
The economic crisis brought about by the COVID-19 pandemic has had adverse
effects on the healthcare system, with up to a 70% drop in revenue reported
from March 2020. Small healthcare facilities have been forced to shut down, and
delayed elective surgical procedures due to social distancing and localized
curfews have negatively impacted healthcare services. As a result, proper
assessment and reporting of clinical cardiac safety data are critical, as it is
essential for product approval and recall. Failure to conduct cardiac safety
evaluations according to legal procedures may result in delayed product approval
and hinder market growth.
In the market for cardiac safety services, the integrated
services segment is expected to dominate during the forecast period. These
services offer a comprehensive suite of cardiac safety services, including
imaging, TQT and profile QT studies, and monitoring of off-target cardiovascular
liability. Certified nurses conduct onsite multichannel telemetry to assess
heart rate and rhythm in real-time, which expedites clinical trials in the
pharmaceutical and biopharmaceutical development cycle.
During the forecast period, the largest regional market for
cardiac safety services is expected to be North America. The market has been
segmented into major regions, which include North America, Europe, the Asia
Pacific, and the Rest of World. North America is considered a mature market for
cardiac safety services and is projected to grow at the highest compound annual
growth rate (CAGR) during the forecast period. The increasing number of
clinical trials being conducted in the region is driving the demand for cardiac
safety services, which is contributing to this growth.
The industry is expected to receive a boost in the coming
years due to an increase in the number of mergers and acquisitions. For
example, in December 2017, ERT acquired iCardiac Technologies, a company known
for its cardiac safety services for clinical studies. This acquisition came
just three months after ERT bought Biomedical Systems, a company that has been
providing clinical cardiac solutions since 1975. iCardiac Technologies has introduced
several innovative methodologies over the past decade, including High Precision
QT and Early Precision QT, which have helped to further advance the field of
cardiac safety services.
One major development in the cardiac safety services market
is the increasing adoption of digital technologies for cardiac safety
monitoring. This includes the use of wearable devices and remote monitoring
solutions, which enable real-time tracking of cardiac function and can improve
patient outcomes. Another development in the market is the growing focus on
personalized medicine and precision cardiology. As our understanding of
cardiovascular diseases improves, there is a greater emphasis on tailoring
treatments to individual patients based on their unique cardiac profiles. This
requires advanced cardiac safety testing solutions that can provide detailed
insights into a patient's cardiac function and help guide treatment decisions.
In response to this trend, several companies in the cardiac safety services
market have developed new, more sophisticated testing technologies. Finally,
there is a growing demand for integrated drug development solutions that can
provide end-to-end support for cardiac safety testing and other aspects of the
drug development process. This includes the use of advanced data analytics and
artificial intelligence to streamline clinical trial operations and improve
patient outcomes. Companies that can provide these integrated solutions are
likely to be well-positioned for growth in the coming years.
Dominating Companies in Cardiac Safety Services Market
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- Koninklijke Philips N.V.
- CLARIO
- BANOOK GROUP
- IQVIA
- BIOTRIAL
- CERTARA
- CELERION
- MEDPACE
- NCARDIA
- RICHMOND PHARMACOLOGY
- PHYSIOSTIM
- SHANGHAI MEDICILON Inc
- PHARMACEUTICAL PRODUCT DEVELOPMENT LLC.
- SGS S.A
- Eurofins
- NEXEL Co., Ltd
- PPD, Inc.
Recent Developments in Cardiac Safety Services Market
- iCardiac Technologies and ERT - In May 2021, it was
announced that iCardiac Technologies, a provider of cardiac safety assessment
services, had been acquired by ERT. The acquisition would allow ERT to expand
its cardiac safety assessment services and provide customers with a more
comprehensive suite of solutions.
- ERT and Bioclinica - In November 2019, it was announced that
ERT had acquired Bioclinica's cardiac safety services division. The acquisition
would allow ERT to expand its cardiac safety services and provide customers
with a more comprehensive suite of solutions.
- BioTelemetry and Geneva Healthcare - In September 2019,
BioTelemetry, a provider of remote cardiac monitoring services, announced that
it had acquired Geneva Healthcare, a provider of cardiac monitoring services
for clinical trials. The acquisition would allow BioTelemetry to expand its
services and provide customers with a more comprehensive suite of solutions.
- LabCorp and Evidera - In June 2019, it was announced that
LabCorp had acquired Evidera, a provider of clinical research services. The
acquisition would allow LabCorp to expand its capabilities in the area of clinical
trial design and execution, including cardiac safety assessment services.
- Cardiovascular Systems Inc. and Gardia Medical - In February
2019, it was announced that Cardiovascular Systems Inc. had acquired Gardia
Medical, a medical device company that develops solutions for treating
cardiovascular disease. The acquisition would allow Cardiovascular Systems Inc.
to expand its product portfolio and provide customers with a more comprehensive
suite of solutions.
- PPD and ECG Scienion - In January 2021, PPD, a global
contract research organization, announced that it had partnered with ECG
Scienion, a provider of cardiac safety assessment services. The partnership
would allow PPD to expand its capabilities in the area of cardiac safety
assessment for clinical trials.
- QPS and Xpansa - In November 2020, it was announced that
QPS, a global contract research organization, had acquired Xpansa, a provider
of data analytics and artificial intelligence solutions. The acquisition would
allow QPS to expand its capabilities in the area of cardiac safety assessment,
including the use of AI and machine learning to analyze cardiac data.
- Premier Research and Synteract - In June 2020, it was
announced that Premier Research and Synteract had merged to form a new contract
research organization. The merger would allow the new company to expand its
capabilities in a range of areas, including cardiac safety assessment for
clinical trials.
- BioTelemetry and Telcare - In May 2018, BioTelemetry
announced that it had acquired Telcare, a provider of cellular-enabled blood
glucose monitoring solutions. The acquisition would allow BioTelemetry to
expand its offerings in the area of remote monitoring for chronic conditions,
including cardiovascular disease
Overall, cardiac safety services are an essential aspect of
drug development and clinical research, helping to ensure the safety and
efficacy of drugs for patients. If you are involved in drug development or
clinical research, it is important to work with a provider that offers
comprehensive cardiac safety services to help ensure the success of your
project.
Cardiac Safety Services Market - Get your Free sample copy
of the Report :::::::::::::::>
1.
Research Sources
We at Zettabyte Analytics have a
detailed and related research methodology focussed on estimating the market
size and forecasted value for the given market. Comprehensive research
objectives and scope were obtained through secondary research of the parent and
peer markets. The next step was to validate our research by various market
models and primary research. Both top-down and bottom-up approaches were
employed to estimate the market. In addition to all the research reports, data
triangulation is one of the procedures used to evaluate the market size of
segments and sub-segments.
Research Methodology
1.1. Secondary Research
The secondary research study involves various sources and databases used
to analyze and collect information for the market-oriented survey of a specific
market. We use multiple databases for our exhaustive secondary research, such
as Factiva, Dun & Bradstreet, Bloomberg, Research article, Annual reports,
Press Release, and SEC filings of significant companies. Apart from this, a
dedicated set of teams continuously extracts data of key industry players and
makes an extensive and unique segmentation related to the latest market
development.
1.2. Primary Research
The primary research includes gathering data from specific domain
experts through a detailed questionnaire, emails, telephonic interviews, and
web-based surveys. The primary interviewees for this study include an expert
from the demand and supply side, such as CEOs, VPs, directors, sales heads, and
marketing managers of tire 1,2, and 3 companies across the globe.
1.3. Data Triangulation
The data triangulation is very important for any market study, thus we
at Zettabyte Analytics focus on at least three sources to ensure a high level
of accuracy. The data is triangulated by studying various factors and trends
from both supply and demand side. All the reports published and stored in our
repository follows a detailed process to obtain a reliable insight for our
clients.
1.4. In-House Verification
To validate the segmentation
and verify the data collected, our market expert ensures whether our research
analyst is considering fine distinction before analyzing the market.
1.5. Reporting
In the end,
presenting our research reports complied in a different format for straightforward
valuation such as ppt, pdf, and excel data pack is done.